TABLE 2.

Results of competing‐risks regression for mortality

	SHR (95% CI)	p‐Value
Unadjusted (N = 6638)
Asthma status (asthma vs. no asthma)	1.04 (0.81, 1.34)	.75
COVID−19 (positive vs. negative)	6.19 (5.14, 7.45)	<.001
Fully adjusted (N = 6008)
Asthma status (asthma vs. no asthma)	1.07 (0.81, 1.41)	.65
COVID−19 (positive vs. negative)	4.50 (3.49, 5.80)	<.001
Age	1.05 (1.05, 1.06)	<.001
Gender (male vs. female)	1.41 (1.16, 1.73)	.001
BAME (yes vs. no)	0.82 (0.51, 1.30)	.39
Obesity (yes vs. no)	0.99 (0.71, 1.38)	.96
No. of hospital stays	1.02 (0.96, 1.08)	.56
Severe asthma (yes vs. no)	0.87 (0.16, 4.67)	.87
HDU (yes vs. no)	2.62 (1.91, 3.58)	<.001
ICU (yes vs. no)	1.81 (1.33, 2.45)	<.001
HDU & ICU interaction	0.25 (0.11, 0.58)	.001
Hypertension, (yes vs. no)	0.88 (0.66, 1.18)	.40
Hyperlipidaemia, (yes vs. no)	0.71 (0.50, 1.02)	.06
Diabetes, (yes vs. no)	1.05 (0.77, 1.43)	.77
Smoking, (yes vs. no)	0.95 (0.62, 1.45)	.81
Alcohol dependence, misuse or alcohol related disease, (yes vs. no)	0.71 (0.44, 1.12)	.14
Ischaemic heart disease, (yes vs. no)	0.97 (0.73, 1.29)	.82
Heart failure, (yes vs. no)	1.33 (0.99, 1.80)	.06
Peripheral vascular disease, (yes vs. no)	1.08 (0.80, 1.46)	.63
Cerebrovascular disease, (yes vs. no)	1.11 (0.83, 1.49)	.48
Renal disease, (yes vs. no)	1.00 (0.75, 1.35)	.98
COPD, (yes vs. no)	1.07 (0.76, 1.51)	.69
Liver disease, (yes vs. no)	1.24 (0.75, 2.08)	.40
Allergic rhinitis, (yes vs. no)	0.97 (0.53, 1.77)	.91
Neoplasms, (yes vs. no)	0.98 (0.75, 1.27)	.87
Dermatitis and eczema, (yes vs. no)	1.23 (0.81, 1.89)	.33
Allergy, (yes vs. no)	1.32 (0.87, 2.01)	.20

Abbreviations: BAME, Black Asian and minority ethnicities; COPD, Chronic obstructive pulmonary disease; COVID‐19, coronavirus disease 2019; HDU, High dependency unit; ICU, intensive care unit; SHR, Subdistribution Hazard Ratio; N, number.

Hazard ratios for co‐morbidities are comparing co‐morbidity present vs. not present.

The bold values mean that the comparisons are statistically significant of less than .05.